Cowen Analysts Give Shire (SHPG) a $225.00 Price Target

Cowen set a $225.00 price objective on Shire (NASDAQ:SHPG) in a report issued on Friday morning. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.

Several other equities analysts have also issued reports on the company. Cantor Fitzgerald set a $222.00 target price on Shire and gave the stock a buy rating in a research note on Wednesday, January 3rd. Piper Jaffray Companies reissued a hold rating on shares of Shire in a research note on Wednesday, January 3rd. Zacks Investment Research lowered Shire from a hold rating to a sell rating in a research note on Tuesday, January 2nd. ValuEngine lowered Shire from a buy rating to a hold rating in a research note on Sunday, December 31st. Finally, Liberum Capital reissued a hold rating on shares of Shire in a research note on Wednesday, December 20th. Two investment analysts have rated the stock with a sell rating, eight have issued a hold rating and eight have issued a buy rating to the company. The company presently has a consensus rating of Hold and an average price target of $212.18.

Shares of Shire (SHPG) traded down $7.76 during trading on Friday, hitting $149.10. The stock had a trading volume of 2,735,100 shares, compared to its average volume of 1,389,720. Shire has a twelve month low of $137.17 and a twelve month high of $192.15. The firm has a market cap of $45,600.00, a price-to-earnings ratio of 28.08, a PEG ratio of 0.84 and a beta of 1.59. The company has a current ratio of 0.98, a quick ratio of 0.52 and a debt-to-equity ratio of 0.55.

Shire (NASDAQ:SHPG) last announced its quarterly earnings results on Friday, October 27th. The biopharmaceutical company reported $3.81 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $3.64 by $0.17. Shire had a return on equity of 14.41% and a net margin of 10.95%. The business had revenue of $3.70 billion for the quarter. During the same period last year, the company earned $3.17 EPS. The business’s revenue for the quarter was up 7.1% on a year-over-year basis. research analysts expect that Shire will post 15 earnings per share for the current year.

Hedge funds have recently bought and sold shares of the business. Seizert Capital Partners LLC raised its position in Shire by 13.3% in the 3rd quarter. Seizert Capital Partners LLC now owns 10,786 shares of the biopharmaceutical company’s stock valued at $1,652,000 after purchasing an additional 1,267 shares in the last quarter. Fisher Asset Management LLC raised its position in Shire by 2.9% in the 3rd quarter. Fisher Asset Management LLC now owns 57,419 shares of the biopharmaceutical company’s stock valued at $8,793,000 after purchasing an additional 1,619 shares in the last quarter. Morningstar Investment Services LLC raised its position in Shire by 53.0% in the 3rd quarter. Morningstar Investment Services LLC now owns 25,882 shares of the biopharmaceutical company’s stock valued at $3,964,000 after purchasing an additional 8,969 shares in the last quarter. Oak Ridge Investments LLC raised its position in Shire by 3.2% in the 2nd quarter. Oak Ridge Investments LLC now owns 81,011 shares of the biopharmaceutical company’s stock valued at $13,389,000 after purchasing an additional 2,528 shares in the last quarter. Finally, Trillium Asset Management LLC raised its position in Shire by 2.3% in the 3rd quarter. Trillium Asset Management LLC now owns 49,083 shares of the biopharmaceutical company’s stock valued at $7,517,000 after purchasing an additional 1,082 shares in the last quarter. 20.19% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION NOTICE: This news story was published by Markets Daily and is the sole property of of Markets Daily. If you are accessing this news story on another site, it was copied illegally and reposted in violation of United States and international copyright and trademark law. The correct version of this news story can be read at https://www.themarketsdaily.com/2018/01/09/cowen-analysts-give-shire-shpg-a-225-00-price-target.html.

Shire Company Profile

Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.

Analyst Recommendations for Shire (NASDAQ:SHPG)

Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply